MDGL vs SGMT
MDGL: Madrigal Pharmaceuticals is a biopharmaceutical company commercializing Rezdiffra, the first and only FDA-approved therapy for adults with metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced liver fibrosis. SGMT: Sagimet Biosciences is a clinical-stage biotech developing oral FASN inhibitors to treat metabolic dysfunction-associated steatohepatitis (MASH) and other metabolic diseases.
Side-by-side fundamentals
| Metric | MDGL | SGMT | Edge |
|---|---|---|---|
| Price as of 2026-07-27 close | $551.25 | $7.11 | |
| Market cap as of 2026-08-03 | $12.7B | $435M | |
| PEG as of 2026-08-03 | -134.35 | n/a | |
| Net margin as of 2026-08-03 | -27.3% | -1393.8% | MDGL higher |
| Gross margin as of 2026-08-03 | +93.1% | n/a | |
| Operating margin as of 2026-08-03 | -27.9% | -1537.0% | MDGL higher |
| ROE as of 2026-08-03 | -50.1% | -37.6% | SGMT higher |
| ROA as of 2026-08-03 | -25.4% | -35.5% | MDGL higher |
| Debt / equity as of 2026-08-03 | 0.63 | 0.00 | SGMT lower |
| Revenue growth (YoY) as of 2026-08-03 | +256.8% | n/a | |
| Beta as of 2026-08-03 | -1.05 | 1.88 | |
| 1-year return as of 2026-07-27 close | +84.7% | -18.2% | MDGL higher |
Fundamentals: market data, as of 2026-08-03. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-27.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.